IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Not Recruiting

Trial ID: NCT03902184


This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.

Official Title

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma

Stanford Investigator(s)

Youn H Kim, MD
Youn H Kim, MD

The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)


Inclusion criteria

SS patients (Cohort 1):

   1. Relapsed and/or refractory stage IVA, IVB SS who have received at least two prior
   systemic therapies;

   2. Prior treatment with mogamulizumab;

   3. Patients should have blood stage B2 at screening based on central evaluation by flow

   4. Feasibility of obtaining at least one skin biopsy at screening;

   MF patients (Cohorts 2 and All comers):

   5. Relapsed and/or refractory stage IB, IIA, IIB, III, IV MF;

   6. Only for Cohort 2: KIR3DL2 expression in at least one expressing skin lesion based on
   central evaluation by IHC;

   7. Patients should have received at least two prior systemic therapies;

   8. Feasibility of obtaining at least one skin biopsy at screening;

   Additional inclusion criteria applicable to all cohorts:

   9. Male or Female, at least 18 years of age;

10. ECOG performance status ≤2;

11. The patient must have a minimum wash-out period of 3 weeks between the last dose of
   prior systemic therapy and the first dose of IPH4102;

12. Patients should have recovered from all non-hematological adverse events related to
   prior therapy to ≤ grade 1 except for alopecia;

13. Adequate baseline laboratory data:


      - Hemoglobin >9 g/dL,

      - Absolute neutrophil count (ANC) ≥1,500/µL,

      - Platelets ≥100,000/µL,


      - Bilirubin ≤1.5 X upper limit of normal (ULN) or ≤3 X ULN for patients with
      Gilbert's disease,

      - Serum creatinine ≤1.5 X ULN,

      - Creatinine clearance ≥30 mL/min, calculated with the Cockcroft & Gault formula,

      - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5 X ULN;

14. Women of childbearing potential (WOCBP): Premenopausal females who had at least one
   menstrual cycle in the past 12 months and capable to become pregnant. They must have a
   negative serum beta-HCG pregnancy test result within seven days from start of

15. Women of childbearing potential and all men (and their female partners of childbearing
   potential) who are sexually active must agree to use adequate method of contraception
   at study entry, during treatment and for at least 9 months (270 days) following the
   last dose of study drug;

16. Signed informed consent form prior to any protocol-specific procedures

Exclusion Criteria:

   1. Patients with evidence of large cell transformation (LCT) based on central histologic
   evaluation at screening;

   2. Receipt of live vaccines within 4 weeks prior to treatment;

   3. Central nervous system (CNS) lymphoma involvement;

   4. Prior administration of IPH4102;

   5. Concurrent enrollment in another clinical trial, unless it is an observational (non -
   interventional) clinical study or the follow-up period of an interventional study;

   6. Autologous stem cell transplantation less than 3 months prior to enrollment;

   7. Prior allogenic transplantation;

   8. Patients who have undergone major surgery ≤ 4 weeks prior to study entry;

   9. Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral,
   bacterial, or fungal infection;

10. Patients who have Hepatitis B Virus infection determined as HBsAg positive and / or
   Hepatitis C Virus infection determined as detection of HCV RNA in serum or plasma by a
   sensitive quantitative molecular method;

11. Known or tested positive for human immunodeficiency virus (HIV);

12. Patients with a history of other malignancies during the past five years apart from
   the disease subject of this study. The following are exempt from the five-year limit:
   non-melanoma skin cancer, lymphomatoid papulosis, resected thyroid cancer,
   biopsy-proven cervical intraepithelial neoplasia, Ductal carcinoma in situ (DCIS) or
   cervical carcinoma in situ

13. Pregnant or breastfeeding women;

14. Known clinically significant cardiovascular disease or condition, including:

      - Class III or IV cardiovascular disease according to the New York Heart
      Association (NYHA) Functional Classification;

      - Any uncontrolled arrhythmia (per the investigator's discretion);

      - Uncontrolled hypertension (per the investigator's discretion).

15. Patients with autoimmune disease on systemic immunosuppressive treatment;

16. Patients with any serious underlying medical condition that would impair their ability
   to receive or tolerate the planned treatment and/or comply with study protocol;

17. Patients with dementia or altered mental status that would preclude understanding and
   rendering of informed consent document.


biological: IPH4102

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mariel Rojas

New Trial Alerts